



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO			Complete If Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Application Number	10/506729	
			Filing Date	September 3, 2004	
			First Named Inventor	Andrew Stocker	
			Art Unit	4615-1626	
			Examiner Name	Not Yet Assigned M. BARKER	
Sheet	1	of	3	Attorney Docket Number	ASZD-P01-664

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.†	Document Number Number-Kind Code* (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
MB	AA	US-2004/0002495-A1	01-01-2004	Philip Sher	
MB	AB	US-3,706,810	12-19-1972	AMERICAN CYANAMIDE <i>Drabander et al.</i>	
MB	AC	US-4,599,198	07-08-1986	DENNIS J. HOOVER	
MB	AD	US-4,668,769	05-26-1987	DENNIS J. HOOVER	
MB	AE	US-4,720,503	01-19-1988	BRUCE E. WITZEL	
MB	AF	US-4,751,231	06-14-1988	WASYL HALCZENKO	
MB	AG	US-4,786,641	11-22-1988	SIEGFRIED GOLDMANN	
MB	AH	US-4,794,120	12-27-1988	PHILIPPE MANOURY	
MB	AI	US-5,863,903	01-26-1999	KARSTEN LUNDGREN	
MB	AJ	US-5,998,463	12-07-1999	BERNARD HULIN	

BF
10/6/06

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.†	Foreign Patent Document Country Code* - Number* - Kind Code* (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	†
MB	BA	WO-00/42213	07-20-2000	The Research Foundation of State University of New York		
MB	BB	WO-00/47206	08-17-2000	Novo Nordisk		
MB	BC	WO-01/05954	01-25-2001	Isis Pharmaceuticals, Inc.		
MB	BD	WO-01/23347	04-05-2001	Novo Nordisk		
MB	BE	WO-01/32654	05-10-2001	Societe de Conseils de Recherches et D'Applications Scientifiques		
MB	BF	WO-01/52825	07-26-2001	Novartis-Erfindungen Verwaltungsgesellschaft M.B.H.		
MB	BG	WO-01/68055	09-20-2001	Pfizer Products Inc.		
MB	BH	WO-01/68092	09-20-2001	Pfizer Products Inc.		
MB	BI	WO-01/68603	09-20-2001	Bristol-Myers Squibb Co.		
MB	BJ	WO-01/94300	12-13-2001	Aventis Pharma Deutschland		
MB	BK	WO-01/96311	12-20-2001	Bristol-Myers Squibb Company		
MB	BL	WO-01/96347	12-20-2001	Bristol-Myers Squibb Company		
MB	BM	WO-02/080844	10-17-2002	Genzyme Corporation		
MB	BN	WO-02/096864	12-05-2002	Aventis Pharma Deutschland GmbH		
MB	BO	WO-02/098348	12-12-2002	Eli Lilly and Company		
MB	BP	WO-02/26714	04-04-2002	Takeda Chemical Industries, Ltd.		
MB	BQ	WO-02/34718	05-02-2002	Richter Gedeon Vegyeszeti Gyar Rt.		
MB	BR	WO-03/037864	05-08-2003	Japan Tobacco Inc.		
MB	BS	EP-0846464	06-10-1998	Pfizer Inc.		
MB	BT	EP-0884050	12-16-1998	Novo Nordisk		
MB	BU	EP-0978279	02-09-2000	Pfizer Products Inc.		
MB	BV	EP-1088824	01-07-2004	Pfizer Products Inc.		
MB	BW	EP-1125580	08-22-2001	Pfizer Products Inc.		
MB	BX	EP-1134213	09-19-2001	Pfizer Inc.		
MB	BY	EP-1136071	09-26-2001	Pfizer Products Inc.		
Examiner Signature	<i>M. P. B.</i>			Date Considered	3-15-06	